Thursday, June 04, 2020 9:59:52 AM
- Gabbert Medical and Arrayit.
Coronaviruses cause illness from the common cold to Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV) and now the novel coronavirus (nCoV “COVID-19”) - a new strain that has not been previously identified in humans up until late 2019 in China.
The lab performs an immunoassay for detection of 2019-Novel Coronavirus (2019-nCoV “COVID-19”) from samples collected by:
1. whole blood by finger stick collection
Tests are conducted in Arrayit’s CLIA, State and Federally approved lab eligible for Medicare, State, Federal and commercial insurance reimbursement and patient/Employer cash pay or self-insurance.
Claims are billed by Arrayit for COVID-19 and Allergy by Doctor authorization.
Arrayit SARS-CoV-2 (COVID-19) Screening Test
Arrayit Corporation offers a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) blood test based on advanced microarray technology and finger stick blood collection through our clinical laboratory in Sunnyvale licensed by the State of California Department of Public Health (CDPH), Clinical Laboratory Improvement Amendments (CLIA) and proficiency-tested by the College of American Pathologists (CAP).
Patient blood specimens are collected on blood cards, shipped to our laboratory and microarray-tested for immunoglobulin G (IgG) antibody reactivity to twelve SARS-CoV-2 proteins in a miniaturized and multiplexed microarray format. High-speed robotics and fully automated data processing ensure speed, accuracy and scalability to a large patient volume.
Healthcare providers receive a 48-72-hour turnaround, digital and easy-to read test reports, and full ordering and report retrieval privileges through our Patient Data Solutions on-line portal.
Doctors can use our SARS-CoV-2 testing services to complement patient diagnoses based on symptoms, and reverse transcription polymerase chain reaction (RT-PCR) tests utilizing upper respiratory nasopharyngeal and oropharyngeal swabs and lower respiratory sputum.
EDUCATIONAL DOCUMENTS IN FIRST DRAFT FORM
With 90-100% accuracy, The Arrayit SARS-CoV-2 test provides actionable IgG antibody data to assist in identifying, managing and treating SARS-CoV-2 illness in patients who may have been exposed to the virus in the workplace and through contact with infected persons at large public gatherings and through travel to domestic and international destinations.
Arrayit SARS-CoV-2 testing offers the advantages of speed, simplicity and high throughput patient testing in a clinical laboratory, and may be particularly useful in identifying carriers that score negative in the SARS-CoV-2 RT-PCR test due to SARS-CoV-2 latency or low virus titers.”
Medical officials are pointing out it’s high pollen season - Allergies cause:
? congestion
? runny nose
? mouth breathing- which causes sore throat These symptoms together present as flu symptoms.
It’s smart to test for Allergies so we can treat them or eliminate them as a cause of the symptoms. The SARS-COV-2 (COVID-19) test is being combined with the Environmental Allergen Panel sample which is derived from the same Finger stick (prick) Blood Card as described above.
https://www.facebook.com/GabbertMedical/posts/covid-19-testing-compels-allergy-testingwe-must-not-confuse-allergy-symptoms-wit/831367814039740/
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM